Hurdles in therapy with regulatory T cells

Area of Science:

• Immunology
• Cell Therapy
• Transplantation Immunology

Background:

• Immune system dysregulation underlies autoimmune diseases, allergies, and transplant rejection.
• Adoptive therapy using regulatory T cells (Tregs) is a promising strategy to modulate immune responses.
• Manufacturing protocols for Tregs are advancing, with products entering early clinical trials.

Purpose of the Study:

• To report the findings of the European Union Cooperation in Science and Technology Action BM1305 (A FACTT).
• To identify critical hurdles impeding the clinical application of Treg therapies in Europe.
• To propose potential solutions to overcome these identified barriers.

Main Methods:

• Consensus building and expert consultation within the A FACTT framework.
• Review of current Treg manufacturing practices and clinical trial status.
• Analysis of regulatory and logistical challenges for cell-based therapies in Europe.

Main Results:

• Several key obstacles hindering widespread Treg clinical application in Europe were identified.
• These hurdles span manufacturing, regulatory pathways, and clinical integration.
• Specific recommendations and potential solutions were formulated by the action group.

Conclusions:

• Addressing the identified hurdles is crucial for the successful clinical translation of Treg therapies.
• Collaborative efforts, as exemplified by A FACTT, are essential to accelerate cell-based tolerance-inducing therapies.
• The findings provide a roadmap for advancing Treg-based treatments in Europe and beyond.